DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc

Authors: Braillard S, Keenan M, Breese KJ, Heppell J, Abbott M, Islam R, Shackleford DM, Katneni K, Crighton E, Chen G, Patil R, Lee G, White KL, Carvalho S, Wall RJ, Chemi G, Zuccotto F, González S, Marco M, Deakyne J, Standing D, Brunori G, Lyon JJ, Castañeda-Casado P, Camino I, Martinez Martinez MS, Zulfiqar B, Avery VM, Feijens PB, Van Pelt N, Matheeussen A, Hendrickx S, Maes L, Caljon G, Yardley V, Wyllie S, Charman SA
Publication: Sci Transl Med
Keywords: dose predictions, fih, first-in-human, gastroplus, IVIVE, PBPK modeling, physiologically based pharmacokinetics
Software: GastroPlus®

New drugs for visceral leishmaniasis that are safe, low cost, and adapted to the field are urgently required.

Evaluating the Role of N-Acetyl-L-Tryptophan in the Aβ 1-42-Induced Neuroinflammation and Cognitive Decline in Alzheimer’s Disease

Evaluating the Role of N-Acetyl-L-Tryptophan in the Aβ 1-42-Induced Neuroinflammation and Cognitive Decline in Alzheimer’s Disease

Authors: Satarker S, Gurram PC, Nassar A, Manandhar S, Vibhavari R, Yarlagadda DL, Mudgal J, Lewis S, Arora D, Nampoothiri M
Publication: Mol Neurobio
Keywords: gastroplus, IVIVE, PBPK modeling, physiologically based pharmacokinetics, preclinical development, tissue concentrations, translational science
Software: GastroPlus®

Alzheimer’s disease (https://www.simulations-plus.com/wp-admin/post.php?post=35654&action=editAD), a neurodegenerative condition previously known to affect the older population, is also now seen in younger individuals.

Log D7.4 and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity

Log D7.4 and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity

Authors: Brandon AM, Baginski SR, Peet C, Dugard P, Green H, Sutcliffe OB, Daéid NN, Nisbet LA, Read KD, McKenzie C
Publication: Drug Test Anal
Keywords: ADME, admet predictor, gastroplus, logP, machine learning, plasma protein binding, QSAR
Software: GastroPlus®

The emergence of new synthetic cannabinoid receptor agonists (SCRAs) onto the illicit drugs market continues to cause harm, and the overall availability of physicochemical and pharmacokinetic data for new psychoactive substances is lacking.

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives

Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives

Authors: Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini AK, Ahmed T
Publication: J Pharm Sci
Keywords: FDA, food effect, gastroplus, pbbm, PBPK modeling, physiologically based pharmacokinetics, regulatory interactions, safe space, vbe, virtual bioequivalence
Software: GastroPlus®

Over the past few decades, physiologically based biopharmaceutics modeling (PBBM) has demonstrated its utility in both new drug and generic product development.

In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software

In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software

Authors: Wang L, Chen J, Chen W, Ruan Z, Lou H, Yang D, Jiang B
Publication: BMC Pharmacol Toxicol
Keywords: dissolution safe space, gastroplus, pbbm, PBPK modeling, physiologically based biopharmaceutics, product specifications, vbe, virtual bioequivalence
Software: GastroPlus®

The prediction of intestinal absorption of various drugs based on computer simulations has been a reality.